FIELD: biotechnology.
SUBSTANCE: invention relates to production of new engineered proteins with binding specificity for serum albumin, which can be used in medicine. Proteins including the ankyrin repeat domain, as well as nucleic acids encoding such proteins and pharmaceutical compositions comprising such proteins for diseases treatment are produced recombinantly.
EFFECT: invention allows a significant increase in blood plasma half-life compared to proteins that do not bind serum albumin.
18 cl, 4 dwg, 3 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMPROVED N-TERMINAL CAPPING MODULES FOR CONSTRUCTED ANKYRIN REPEAT PROTEINS | 2011 |
|
RU2636552C2 |
| MODIFIED BINDING PROTEINS, INHIBITING INTERACTION OF VEGF-A RECEPTOR | 2011 |
|
RU2605309C2 |
| BINDING PROTEINS, INHIBITING INTERACTION OF VEGF-A RECEPTOR | 2009 |
|
RU2650765C1 |
| BINDING PROTEINS INHIBITING VEGF-A RECEPTOR INTERACTION | 2009 |
|
RU2550258C2 |
| BINDING PROTEINS COMPRISING AT LEAST TWO REPEAT DOMAINS AGAINST HER2 | 2013 |
|
RU2664464C9 |
| RECOMBINANT BINDING PROTEINS AND THEIR USE | 2017 |
|
RU2778346C2 |
| GLYCOSYLATED CONGUGATES OF MOLECULES WITH REPEATING MOTIF | 2010 |
|
RU2574201C2 |
| RECOMBINANT PROTEIN EXPRESSION IN DOUBLE-STRAND C FORM | 2006 |
|
RU2412253C2 |
| PHAGE DISPLAY ON pIX PROTEIN INDEPENDENT FROM SIGNAL SEQUENCE | 2010 |
|
RU2540010C2 |
| NON-NATURAL CLASS 3 SEMAPHORINS AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2722832C2 |
